The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese
© Lim et al.; licensee BioMed Central Ltd. 2013
Received: 8 January 2013
Accepted: 25 April 2013
Published: 8 May 2013
Genetic polymorphisms observed in various disease states associated with sensitivity or resistance to specific treatments have been a robust area of investigation for decades, with the potential to allow clinicians to make evidence-based decisions on the appropriate course of treatment. This study aimed to evaluate whether genetic polymorphisms of the signal transducer and activator of transcription 6 gene (STAT6) could be associated with a sustained virological response (SVR) among patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2) who were treated with peginterferon plus ribavirin (PEG-IFNα-RBV). We analyzed the associations between SVR to PEG-IFNα-RBV therapy and 4 single nucleotide polymorphisms (SNPs) in STAT6. This study included Taiwanese Chinese patients infected with either HCV-1 (n = 265) or HCV-2 (n = 195) in the presence or absence of an SVR. Among the STAT6 SNPs examined, the dosage effect of the A allele and allele frequency in rs1059513 were inversely correlated with SVR in patients infected with HCV-1 (P = 0.0179 and P = 0.0235, respectively). This effect was not observed in patients infected with HCV-2. The GG, GGG, and GGGC STAT6 haplotypes comprising 2, 3, and 4 SNPs (rs1059513, rs703817, rs324015, and rs3024974) were found to be associated with SVR, and their presence may increase the probability of a successful treatment outcome in patients infected with HCV-1 (P = 0.0273, 0.0352, and 0.0368, respectively). Moreover, a multivariate logistic regression model for predicting an SVR revealed that the presence of the GGGC haplotype carriers mutually affected the outcome of PEG-IFNα-RBV treatment. The presence of STAT6 SNPs and the association with SVR demonstrated that STAT6 polymorphisms might influence the therapeutic outcomes of patients infected with HCV-1 under standard-of-care (SOC) treatment.
KeywordsHepatitis C virus Standard of care treatment Sustained virological response Signal transducer and activator of transcription 6
Hepatitis C is a common infectious disease caused by hepatitis C virus (HCV). Infection with HCV is the most common cause of chronic liver disease, hepatoma, and liver transplantation [1–3]. Typically, HCV spreads through exposure to infected blood, especially via intravenous drug abuse, which is a major route of transmission. In addition to blood-borne exposure, HCV may also spread through sexual contact and vertical transmission, albeit at lower risk . It is estimated that approximately 170 million people worldwide are infected with HCV [4, 5].
The standard-of-care (SOC) treatment for chronic hepatitis C includes a combination of pegylated interferon alpha (PEG-IFNα) and ribavirin (RBV) [6, 7]. The effectiveness of 2 types of peginterferon, alfa-2a and alfa-2b, both differing in their pharmacokinetic and chemical properties, has been determined [8, 9]. Peginterferon alfa-2a plus ribavirin is more effective in treating chronic hepatitis C than interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone . In general, successful treatment is defined as the persistent absence of serum HCV RNA for 6 months or longer post therapy, known as a sustained virological response (SVR) .
IFNα exert multifunctional biological activities and consists of highly homologous proteins mediated by binding to the receptor chains, IFNαR1 or IFNαR2 . Binding of IFNα to its receptor leads to its activation via two receptor-associated tyrosine kinases (Tyk2) and Janus kinases 1 and 2 (JAK kinases 1 and 2), which in turn triggers the activation of cytoplasmic factors, namely, the STAT (signal transducers and activators of transcription) family of proteins . STAT6 is a cytosolic protein, the tyrosine phosphorylation of which is catalyzed by JAK kinases 1 and 2 . Subsequently, phosphorylated STAT6 proteins dimerize via their SH2 domains and translocate into the nucleus, where they bind to response elements of target genes and regulate cytokine production [11, 12]. STAT6 induces two forms of cytokines, IL-4 and IL-13. Formation of STAT homo/heterodimer in response to IFNα activation may initiate transcription of several genes, including genes encoding the transcription factor IFN regulatory factor 1 (IRF-1) and IFN-stimulated gene factor 3 (ISGF3). The ISGF3 complex may trigger several subsets of genes termed IFN-stimulated response elements (ISREs) by binding to different parts of cis-acting elements . The JAK/STAT signaling pathway is activated when the cytokine interleukins 4 (IL-4), IL-12, and/or type I interferon (IFN) bind to their respective receptors. Since STAT6 protein is essential for responsiveness to IL-4 and IL-12, STAT6-deficient mice do not produce significant numbers of type 2 CD4+ T cells, thereby blocking the differentiation of these cells [13, 14]. Furthermore, multiple studies have demonstrated that STAT6 knockout mice are resistant to tumor growth and spontaneous metastatic disease . Therefore, IFN-mediated activation of STAT6 occurs via production of secreted IL-1Ra during inflammatory responses . STAT6 activation has been reported to play an important role in the regulation of genes responsible for their antitumor or antiviral effects.
Previous studies have demonstrated that the SVR rates for patients infected with HCV genotype 1 (HCV-1) are significantly lower than the rates for those who are infected with HCV genotype 2 (HCV-2). In order to validate the potentially useful prognostic biomarkers that are able to predict SVR during early treatment, previous studies have used real-time PCR to estimate the expression profiles of 68 messenger RNAs isolated from HCV-1 infected patients, as well as their correlation with SVR . Investigators found that STAT6 expression levels are highly correlated with SVR. It has been suggested that, in addition to inducing important molecular pathways, the expression of several early genes during HCV therapy may also influence the capacity of residual SVR.
In the present study, we investigated the association between single nucleotide polymorphisms (SNPs) in the STAT6 gene and their susceptibility to SVR in Chinese patients in Taiwan receiving PEG-IFNα-RBV treatment. Our results support the hypothesis that STAT6 is a potential candidate gene for predicting therapeutic outcomes of HCV-1 infected patients.
In the present study, 265 patients infected with HCV-1 and 195 patients infected with HCV-2 at the China Medical University Hospital, Taichung, Taiwan were enrolled and actively observed. All participating subjects provided informed consent, and the study protocol was approved by the chairman of the Ethics Committee of the China Medical University Hospital in accordance with the guidelines of the Declaration of Helsinki. Diagnosis of HCV infection was based on persistent elevation of serum transaminase levels for at least 6 months and serum anti-HCV positivity, coupled with the periodic detection of serum HCV RNA. Patients positive for hepatitis B surface antigen, antibodies, and human immunodeficiency virus 1 and 2 were excluded in this study. Patients received weekly injections of PEG-IFNα (1.5 μg/kg body weight) plus body weight–adapted doses of RBV (800 mg/day for < 60 kg; 1000 mg/day for 60–75 kg; 1200 mg/day for > 75 kg) by oral administration for 48 weeks (HCV-1) or 24 weeks (HCV-2).
Selection of representative STAT6 SNPs was based on SNP genotype information, downloaded in December 2008 from the HapMap Chinese Han in Beijing (CHB) + JPT population. HapMap genotypes were further analyzed via Haploview software (version 4.2; Broad Institute, Cambridge, MA, USA). Tag SNPs were selected by using the Tagger function according to the following criteria: (1) a minor allele frequency (MAF) in the HapMap CHB + JPT population of > 0.10; and (2) a genotyping score of ≥ 0.6 (Illumina, Inc., San Diego, CA), as recommended by the manufacturer, to achieve a successful genotyping rate. Four SNPs in the STAT6 gene met the above criteria and were selected, including rs1059513 (S1; A/G at 3′ UTR), rs703817 (S2; A/G at 3′ UTR), rs324015 (S3; A/G at 3′ UTR), and rs3024974 (S4; C/T at boundary of intron 17).
HCV genotyping and RNA measurements
Genotyping of HCV according to the classification of Simmonds et al. was performed by a reverse hybridization assay (INNO LiPA HCV-II; Innogenetics, Ghent, Belgium). The virological response was assessed by qualitative HCV RNA assays with a lower sensitivity of 30–50 IU/ml (HCV Amplicor™ 2.0, Roche Diagnostics, Branchburg, NJ, USA). According to the qualitative HCV RNA results (reported in copies/mL), patients were defined as (1) sustained virological responders (HCV RNA undetectable at week 24 posttreatment) and (2) non-sustained virological responder (HCV RNA detected at week 24 posttreatment). Thus, the subjects were classified as either SVR (+) or SVR (−), respectively.
Genomic DNA extraction and genotyping
Genomic DNA was isolated from the peripheral blood of all participants by using a commercial kit (Genomic DNA kit; QIAGEN, Valencia, CA, USA) according to the manufacturer’s instructions. Four STAT6 polymorphisms were detected by an allele-specific extension method and ligation assay kit (Illumina, San Diego, CA, USA), in accordance with the manufacturer’s instructions.
Gender, age, body mass index (BMI), and viral load differences between SVR (+) and SVR (−) groups were estimated using the Mann–Whitney U test. The differences between genotypes and each of the above mentioned parameters were estimated using the Kruskal–Wallis test. The association of each SNP with SVR was assessed using the chi-square (χ2) test or Fisher’s exact test. Genotype and allele frequencies in SVR (+) and SVR (−) patients were compared, and odds ratios (ORs) with a 95% confidence interval (CI) were estimated by applying an unconditional logistic regression model. Haplotype analysis using a sliding window mode and Hardy–Weinberg equilibrium (HWE) analysis were performed using the PLINK program (version 1.07; http://pngu.mgh.harvard.edu/purcell/plink/) . The distribution of each haplotype frequency was identified using Phase version 2.1 (University of Chicago, Chicago, IL, USA), a computational tool based on Bayesian methods . Multivariate logistic regression analysis was used to predict the independent variables that correlated with a therapeutic response. An OR at a 95% CI was employed for this analysis. Statistical tests were performed using SPSS software (version 20.0 for Windows; SPSS Inc., Chicago, IL, USA). Statistical significance was defined as P < 0.05 and was two-sided. Screening and construction of linkage disequilibrium (LD) plots were performed using Haploview software (version 4.2).
Characteristics of the HCV genotype 1 and 2 infected patients receiving PEG-IFNα-RBV therapy
HCV genotype 1 (HCV-1)
HCV genotype 2 (HCV-2)
Number of patients
Age (mean ± SD)
52.17 ± 10.27
50.69 ± 10.60
54.52 ± 9.29
51.62 ± 10.89
51.15 ± 11.16
56.47 ± 5.86
BMI (mean ± SD)
24.6 ± 3.1
24.2 ± 2.9
25.2 ± 3.3
24.5 ± 3.5
24.5 ± 3.6
24.5 ± 2.7
Degree of inflammatory activity (A0/A1-3) c
Stage of fibrosis (F0/F1-4) c
AST (U/L) (mean ± SD)
76.15 ± 41.24
90.91 ± 61.12
84.26 ± 63.45
78.12 ± 34.03
ALT (U/L) (mean ± SD)
118.56 ± 75.99
108.05 ± 74.97
120.67 ± 104.63
100.71 ± 44.76
Platelet (× 10 3 /μl) (mean ± SD)
176.4 ± 56.7
154.9 ± 59.5
174.4 ± 52.4
125.5 ± 41.8
Viral load (× 10 6 )
12.1 ± 16.4
11.0 ± 16.5
13.9 ± 16.2
11.0 ± 19.0
10.3 ± 17.8
18.4 ± 27.9
Four single nucleotide polymorphisms in the STAT6 gene in 265 HCV-1 and 195 HCV-2 infected patients receiving PEG-IFNα-RBV therapy with or without a SVR in a Chinese population in Taiwan
Position in STAT6
HWE (P value)
HWE (P value)
Intron 17 (boundary)
Association of tagging SNPs of STAT6 with therapeutic response and SVR
Genotype frequencies of STAT6 single nucleotide polymorphisms (SNPs) in HCV-1 and HCV-2 infected patients receiving PEG-IFNα-RBV therapy with and without a SVR in a Chinese population in Taiwan
OR (95% CI)
OR (95% CI)
0.40 (0.18, 0.87)
0.90 (0.19, 4.19)
A/A + A/G
A/A + A/G
0.61 (0.24, 1.58)
0.64 (0.38, 1.09)
1.78 (0.60, 5.27)
A/A + A/G
0.64 (0.39, 1.05)
A/A + A/G
2.05 (0.69, 6.06)
1.05 (0.52, 2.12)
0.43 (0.10, 1.85)
0.97 (0.55, 1.71)
0.78 (0.20, 3.09)
A/A + A/G
0.99 (0.58, 1.69)
A/A + A/G
0.63 (0.17, 2.31)
0.34 (0.07, 1.62)
2.05 (0.22, 19.19)
0.25 (0.05, 1.19)
2.36 (0.23, 24.33)
C/C + C/T
0.31 (0.07, 1.43)
C/C + C/T
2.15 (0.24, 19.55)
Allele frequencies of STAT6 single nucleotide polymorphisms in HCV-1 and HCV-2 infected patients receiving PEG-IFNα-RBV therapy with and without a SVR in a Chinese population in Taiwan
OR (95% CI)
OR (95% CI)
0.42 (0.20, 0.91)
0.90 (0.20, 4.01)
0.72 (0.49, 1.06)
2.05 (0.77, 5.45)
1.02 (0.71, 1.45)
0.65 (0.32, 1.34)
1.01 (0.66, 1.56)
1.07 (0.45, 2.56)
Frequencies of the STAT6 haplotypes and the association with SVR
Details of sex-adjusted haplotype frequency analysis for 2-SNP, 3-SNP, and 4-SNP windows showing the most significant results among all possible sliding windows in HCV-1 infected patients
Distribution of haplotype frequencies from SNPs of STAT6 gene in 265 HCV-1 infected populations and their associations with SVR
SVR (+) (%)
SVR (−) (%)
OR (95% CI)
1.04 (0.67, 1.61)
1.25 (0.23, 6.91)
0.41 (0.07, 2.50)
1.06 (0.75, 1.51)
0.70 (0.48, 1.04)
2.28 (1.06, 4.89)
Multivariate logistic regression analysis
Predictive factors associated independently with the SVR to PEG-IFNα-RBV therapy in HCV-1 infected populations by multivariate logistic regression analysis
OR (95% CI)
2.32 (1.03, 5.23)
0.97 (0.94, 1.00)
0.92 (0.85, 1.00)
HCV-RNA levelδ (low/high)
8.11 (0.98, 67.32)
The present study examined the genetic association of HCV infection under PEG-IFNα-RBV therapy on a responsive gene, STAT6, and responsiveness of treatment. We confirmed that this gene, located on chromosome 12, is a novel candidate susceptibility gene. The results showed that rs1059513 at the 3′ UTR of STAT6 may be associated with SVR rates under SOC treatment. Therapeutic outcome association studies showed that the presence of the GGGC haplotype was significantly associated with a higher rate of SVR (OR = 1.06–4.89) in HCV-1 infected but not HCV-2 infected populations. By using multivariate logistic regression analyses, we observed that the GGGC haplotype, age of entry, and viral load may act interactively to influence the therapeutic outcomes. This result suggests that the SVR rates of PEG-IFNα-RBV treatment could, at least partially, depend on STAT6 activation.
Thus far, the standard treatment regimen for chronic hepatitis C infection has been a combination of PEG-IFNα and RBV . About 50% of treatment-naïve populations will typically achieve SVR by using this regimen . The SVR rate is markedly higher in HCV-2/3 infected patients than in HCV-1 infected patients (~ 85% versus 40%) . In order to identify the biomarkers that distinguish the profiles of HCV therapeutic responsiveness, Younossi and colleagues  collected RNA transcripts from peripheral blood mononuclear cells (PBMCs) of 68 HCV-infected patients under PEG-IFNα-RBV treatment. After preparing expression profiles of patients under this treatment, the investigators observed that genetic expression of STAT6 and cytokine signaling 1 are putative predictive markers that correlate with SVR . In support of this finding, we also observed a correlation between STAT6 genetic polymorphisms and SVR.
During viral infections, innate immunity remains the most important first line of defense in the body. Viral nucleic acids are detected by endosomal Toll-like receptors (TLRs) and cytoplasmic RIG-I–like receptors (RLRs), which subsequently induce the production of type 1 IFN to inhibit viral replication . Consequently, many cytokines (including type 1 IFNs) trigger the IFN-stimulated gene expression cascade through the canonical JAK-STAT signaling pathway . Previous studies have shown that STAT6 activation is ubiquitously detected during viral infections, concluding that STAT6 may play a fundamental role in the defense mechanism against viral infections . Viral load, age of entry into the study, and BMI were not significantly different among the STAT6 genotypes of our enrolled populations. Thus, it is unlikely that specific STAT6 genotypes predispose individuals to infection with HCV or contribute to the process of spontaneous viral elimination.
Studies using a microarray platform to examine the differential gene expression profiles of IL-4–stimulated B cells between wild-type and Stat6−/− mice were recently performed . Seventy known genes were found to be differentially expressed with significant discrepancies between the 2 mouse groups, which were all negatively or positively regulated by STAT6 via a palindromic consensus sequence TTC(N)2-4GAA . In addition, STAT6 remains a critical determinant in the polarization and differentiation process of T-helper type 2 (Th2) cells in a Stat6 knockout mouse model . The expression levels of Th2-related cytokines (including IL-4, IL-5, and IL-13) were diminished in this mouse model . Moreover, STAT6 may trigger a Th1 response by enhancing the production of IL-12 through the inhibition of IL-10 production in dendritic cells . Therefore, STAT6 is also a critical factor in the homeostasis of inflammatory and hypersensitivity immune responses other than those associated with viral immunity.
Several reports have provided strong evidence that patients infected with HCV-1 will have approximately a 50% probability (in Caucasians) or 80% probability (in African Americans) of a poor response toward PEG-IFNα-RBV treatment . Although viral clearance rates have been strongly associated with clinical features of HCV, for example: gender, age < 40 years, low HCV RNA levels pre-treatment, in the absence of liver cirrhosis, and HCV genotypes 2/3 . Table 7 lists 11 patients with low viremia. Fried et al. concluded that HCV RNA level is one of the main factors affecting treatment outcome; therefore, we performed multivariate analysis to check whether HCV RNA level is an independent factor of treatment outcome. We first determined the HCV RNA baseline without categorizing the patients; however, in this analysis, P = 0.182 and OR = 1.00. This result led us to conclude that it is not the best model for prediction of treatment outcome. Therefore, we categorized the HCV RNA level according to the description of Fujimoto et al., with low HCV RNA level <100 KIU/ml by Amplicore-monitor assay and performed statistical analysis, and the results for this analysis are more obviously (P = 0.050, OR = 8.11).
Many investigators continue to monitor the host genetic factors that may relate to clinical outcomes to provide custom-made therapy for HCV infection. In our study, the overall achievement response rates of SVR were less than 62% and 92% in the HCV-1 and HCV-2 populations, respectively. Thus, a reliable prediction of a subject as a potential non-viral responder (NVR) at the start of treatment would allow the clinician to make appropriate, evidence-based decisions on the compatibility of future treatment, thereby reducing side effects and/or the cost of treatment.
The contributions of host genetic factors to HCV-2/3 clearance are relatively small compared with HCV-1 clearance, because the former is more likely to be eliminated by SOC therapy . In the present study, we observed an association between the STAT6 haplotype GGGC and the rate of SVR, although its statistical significance in the HCV-1 infected populations based on estimation by multivariate logistic regression was marginal. The frequency of the GGGC allele in our population was small, whether the frequency of this haplotype is significant in other ethnic groups remains unknown. We propose that this STAT6 haplotype GGGC might play a role in the outcome of PEG-IFNα-RBV therapy (adjusted r2 = 11.2%). The linkage among the STAT6 polymorphisms and SVR should be confirmed in future studies with larger sample sizes. Moreover, the significance of the genetic effects of STAT6 on other racial and ethnic groups remains to be elucidated.
The mechanisms of action of the aforementioned 4 SNPs located within the 3′ UTR and intronic regions of STAT6 gene are hampered by the lack of published functional studies on these polymorphisms and warrants further investigation at the molecular level.
This study provides evidence that the STAT6 genetic polymorphisms are related to the susceptibility of HCV-infected patients, especially HCV-1 infected patients to SVR. Furthermore, an outcome measure of haplotype GGGC in the clinical response was identified. Thus, STAT6 may play an important role in a broad range of antiviral activities under PEG-IFNα-RBV treatment.
This study was supported by National Science Council, Executive Yuan, Taiwan, R.O.C. (NSC101-2320-B-039-038 and NSC101-2320-B-039-007-MY3), China Medical University Hospital, Taichung, Taiwan (DMR-99-093), China Medical University, Taichung, Taiwan (CMU98-ASIA-04), and in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004).
- Alter MJ: Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007, 13: 2436-2441.PubMed CentralView ArticlePubMed
- Bowden DS, Berzsenyi MD: Chronic hepatitis C virus infection: genotyping and its clinical role. Future Microbiol. 2006, 1: 103-112. 10.2217/174609188.8.131.52.View ArticlePubMed
- Bellentani S, Miglioli L, Bedogni G, Croce LS, Tiribelli C: Epidemiology of hepatitis C virus infection. Minerva Gastroenterol Dietol. 2005, 51: 15-29.PubMed
- Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005, 5: 558-567. 10.1016/S1473-3099(05)70216-4.View ArticlePubMed
- Pellicano R, Mladenova I, Dimitrova SM, Bruno CM, Sciacca C, Rizzetto : The epidemiology of hepatitis C virus infection. An update for clinicians. Minerva Gastroenterol Dietol. 2004, 50: 1-7.PubMed
- Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G: Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010, 138: 116-122. 10.1053/j.gastro.2009.10.005.View ArticlePubMed
- Bosques-Padilla F, Trejo-Estrada R, Campollo-Rivas O, Cortez-Hernandez C, Dehesa-Violante M, Maldonado-Garza H, Perez-Gomez R, Cabrera-Valdespino A: Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Ann Hepatol. 2003, 2: 135-139.PubMed
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002, 347: 975-982. 10.1056/NEJMoa020047.View ArticlePubMed
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001, 358: 958-965. 10.1016/S0140-6736(01)06102-5.View ArticlePubMed
- Sokal EM, Bourgois A, Stephenne X, Silveira T, Porta G, Gardovska D, Fischler B, Kelly D: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol. 2010, 52: 827-831. 10.1016/j.jhep.2010.01.028.View ArticlePubMed
- Wurster AL, Tanaka T, Grusby MJ: The biology of Stat4 and Stat6. Oncogene. 2000, 19: 2577-2584. 10.1038/sj.onc.1203485.View ArticlePubMed
- Dickensheets HL, Venkataraman C, Schindler U, Donnelly RP: Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc Natl Acad Sci USA. 1999, 96: 10800-10805. 10.1073/pnas.96.19.10800.PubMed CentralView ArticlePubMed
- Galka E, Thompson JL, Zhang WJ, Poritz LS, Koltun WA: Stat6 (null phenotype) human lymphocytes exhibit increased apoptosis. J Surg Res. 2004, 122: 14-20. 10.1016/j.jss.2004.05.004.View ArticlePubMed
- Zhang S, Bernard D, Khan WI, Kaplan MH, Bramson JL, Wan Y: CD4+ T-cell-mediated anti-tumor immunity can be uncoupled from autoimmunity via the STAT4/STAT6 signaling axis. Eur J Immunol. 2009, 39: 1252-1259. 10.1002/eji.200839152.View ArticlePubMed
- Ostrand-Rosenberg S, Sinha P, Clements V, Dissanayake SI, Miller S, Davis C, Danna E: Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immunosurveillance against primary tumors and metastatic disease. Cancer Immunol Immunother. 2004, 53: 86-91. 10.1007/s00262-003-0446-z.View ArticlePubMed
- Wan L, Lin CW, Lin YJ, Sheu JJC, Chen BH, Liao CC, Tsai Y, Lin WY, Lai CH, Tsai FJ: Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer. J Cell Mol Med. 2008, 12: 876-888. 10.1111/j.1582-4934.2008.00143.x.PubMed CentralView ArticlePubMed
- Younossi ZM, Baranova A, Afendy A, Collantes R, Stepanova M, Manyam G, Bakshi A, Sigua CL, Chan JP, Iverson AA, Santini CD, Chang SY: Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. Hepatology. 2009, 49: 763-774. 10.1002/hep.22729.View ArticlePubMed
- Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS: Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993, 74: 2391-2399. 10.1099/0022-1317-74-11-2391.View ArticlePubMed
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007, 81: 559-575. 10.1086/519795.PubMed CentralView ArticlePubMed
- Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21: 263-265. 10.1093/bioinformatics/bth457.View ArticlePubMed
- The French METAVIR Cooperative Study Group: Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994, 20: 15-20.View Article
- Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, Tsujimura T, Takeda K, Fujita T, Takeuchi O, Akira S: Cell type-specific involvement of RIG-I in antiviral response. Immunity. 2005, 23: 19-28. 10.1016/j.immuni.2005.04.010.View ArticlePubMed
- Gale M, Foy EM: Evasion of intracellular host defence by hepatitis C virus. Nature. 2005, 436: 939-945. 10.1038/nature04078.View ArticlePubMed
- Chen H, Sun H, You F, Sun W, Zhou X, Chen L, Yang J, Wang Y, Tang H, Guan Y, Xia W, Gu J, Ishikawa H, Gutman D, Barber G, Qin Z, Jiang Z: Activation of STAT6 by STING is critical for antiviral innate immunity. Cell. 2011, 147: 436-446. 10.1016/j.cell.2011.09.022.View ArticlePubMed
- Schroder AJ, Pavlidis P, Arimura A, Capece D, Rothman PB: Cutting edge: STAT6 serves as a positive and negative regulator of gene expression in IL-4-stimulated B lymphocytes. J Immunol. 2002, 168: 996-1000.View ArticlePubMed
- Schindler U, Wu P, Rothe M, Brasseur M, McKnight SL: Components of a Stat recognition code: evidence for two layers of molecular selectivity. Immunity. 1995, 2: 689-697. 10.1016/1074-7613(95)90013-6.View ArticlePubMed
- Kaplan MH, Schindler U, Smiley ST, Grusby MJ: Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity. 1996, 4: 313-319. 10.1016/S1074-7613(00)80439-2.View ArticlePubMed
- Yao Y, Li W, Kaplan MH, Chang CH: Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. J Exp Med. 2005, 201: 1899-1903. 10.1084/jem.20050324.PubMed CentralView ArticlePubMed
- Gao B, Hong F, Radaeva S: Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology. 2004, 39: 880-890. 10.1002/hep.20139.View ArticlePubMed
- Fujimoto Y, Ochi H, Maekawa T, Abe H, Hayes CN, Kumada H, Nakamura Y, Chayama K: A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients. J Hepatol. 2011, 54: 629-639. 10.1016/j.jhep.2010.07.021.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.